Abstract P3 11 23: GDC 0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone positive breast cancer models
The phosphatidylinositol 3kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway is a major regulator of tumor cell growth, proliferation and survival. Hotspot mutations of PIK3CA are common in all subtypes of breast cancer with a prevalence of approximately 30% GDC 0077 is a potent ATP competitive inhibitor of PI3K alpha (IC50 0.038 0.003 nM) thereby inhibiting the phosphorylation of membranebound PIP2 to PIP3. Biochemically, GDC 0077 is more than 300fold selective over the other Class I PI3K isoforms, beta, delta, and gamma, and more than 2000 fold more selective over PI3K class II and III family members. Importantly, GDC 0077 is more selective for mutant versus wild type PI3K alpha in cell based assays. Mechanism of action studies indicate that GDC 0077 treatment leads to degradation of the mutant PI3K alpha protein in a proteasome dependent fashion, without changing WT PI3K alpha levels. Drug treatment results in sustained reduction of PI3K pathway biomarkers pAkt and pPRAS40, inhibition of cell proliferation, and increased apoptosis in human PIK3CA mutant breast cancer cell lines, to a greater extent than other non degrading inhibitors such as alpelisib. Combination studies of GDC 0077 with the CDK4/6 inhibitor palbociclib demonstrate a stronger effect in estrogen depleted HR+ PIK3CA mutant breast cell lines, compared to cells grown in the presence of estrogen. Daily dosing of GDC 0077 in PIK3CA mutant breast cancer patient derived xenograft (PDX) models (n=4) resulted in tumor regressions, induction of apoptosis and a reduction of pAkt, pPRAS40, and pS6RP in a dose dependent fashion. In vivo combination efficacy studies of GDC 0077 with fulvestrant and palbociclib also indicate the triple combination results in the greatest efficacy. Collectively, our preclinical data support evaluation of GDC 0077 in a triple combination with endocrine therapy and CDK4/6 inhibition in the clinic, in patients with locally advanced or metastatic hormone receptor positive breast cancer whose tumors harbor mutant PIK3CA. Citation Format: Kyle Edgar, Rebecca Hong, Kyung Song, Steven Schmidt, Marc Hafner, Alfonso Arrazate, Erin Williams, Cecile De La Cruz, Jason Oeh, Deepak Sampath, Steve Staben, Lori Friedman. GDC 0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone positive breast cancer models [abstract] In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10 14; San Antonio, TX. Philadelphia (PA) AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3 11 23.